Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis

Modern Rheumatology

Volumn 21, Issue 4, 2011, Pages 436-439

  Shima, Yoshihito ^a   Tomita, Tetsuya ^a   Ishii, Taeko ^a   Morishima, Atsuyoshi ^a   Maeda, Yuichi ^b   Ogata, Atsushi ^a   Kishimoto, Tadamitsu ^c   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Ankylosing spondylitis; IL 6; Tocilizumab

Indexed keywords

BETAMETHASONE; CYTOKINE; INDOMETACIN; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; JAPANESE; KNEE PAIN; LOW BACK PAIN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SHOULDER PAIN;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; HLA-B27 ANTIGEN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 83255164666     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0416-9     Document Type: Article

References (19)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369: 1379-90. (Pubitemid 46590387)
2. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1beta and IFNgamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33:927-31. (Pubitemid 24324807)
3. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo- controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48: 1667-75. (Pubitemid 36682375)
4. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230-6. (Pubitemid 37409337)
5. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis. 2003;62:1218-20. (Pubitemid 37500631)
6. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6: 843-54.
7. Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis. Ann Rheum Dis. 1973;32:354-63.
8. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;12:2286-91.
9. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-5.
10. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21: 1694-8. (Pubitemid 24285485)
11. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum. 2006;54:678-81. (Pubitemid 43228648)
12. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67:511-7. (Pubitemid 351498433)
13. Hayer S, Niederreiter B, Nagelreiter I, Smolen J, Redlich K. Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Ann Rheum Dis. 2010;69:1403-6.
14. Falkenbach A, Herold M, Wigand R. Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year? Rheumatol Int. 2000;19:149-51. (Pubitemid 30242751)
15. Wendling D, Racadot E, Toussirot E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol. 1996;35:1330. (Pubitemid 27032963)
16. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010;69:2217-8.
17. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 in spondylarthritis. Joint Bone Spine. 2010;77:624-5.
18. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010;77:625-6.
19. Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009;61:1762-4.